Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2024 and Provides Financial Expectations for 2025
Portfolio Pulse from
Alkermes plc reported its financial results for 2024, showing total revenues of $1.56 billion and a significant 18% increase in net sales of proprietary products. The company achieved a GAAP net income of $372 million and earnings per share of $2.20. Alkermes is continuing its Phase 2 studies for ALKS 2680 in narcolepsy, with data expected in the second half of 2025.
February 12, 2025 | 12:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Alkermes reported strong financial results for 2024 with $1.56 billion in revenue and an 18% increase in proprietary product sales. The company also announced ongoing Phase 2 studies for ALKS 2680 in narcolepsy.
The strong financial performance, including significant revenue growth and increased sales of proprietary products, is likely to positively impact Alkermes' stock price. Additionally, the ongoing Phase 2 studies for ALKS 2680 could further boost investor confidence.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100